Drugs for Medulloblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 260)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Carboplatin |
Approved |
Phase 4 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
2 |
|
Coenzyme M |
Approved, Investigational |
Phase 4 |
|
3375-50-6 |
598 23662354 |
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-Mercaptoethanesulphonic acid
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
Bristol myers squibb brand OF mesna
|
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzym m
Coenzyme m
CoM
D-7093
HS-CoM
Kendrick brand OF mesna
Mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
NSC-113891
Reduced coenzyme m
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
Β-mercaptoethanesulfonate
Β-mercaptoethanesulfonic acid
Β-mercaptoethanesulphonate
Β-mercaptoethanesulphonic acid
|
|
3 |
|
Thiotepa |
Approved, Investigational |
Phase 4 |
|
52-24-4 |
5453 |
Synonyms:
Girostan
NSC-6396
Rethio
Tepadina
Tepadina®|Thioplex®
Tespa
Tespamin
Thio tepa
|
Thiophosphamide
Thioplex
Thio-tepa
THIOTEPA
THIOTEPA 或 THIOTEPA
Triethylenethiophosphoramide
Tris(1-aziridinyl)phosphine sulfide
|
|
4 |
|
Etoposide |
Approved |
Phase 3 |
|
33419-42-0 |
36462 |
Synonyms:
(-)-Etoposide
(−)-ETOPOSIDE
(-)-etoposide|Etopophos®|Toposar®|trans-etoposide|VePesid®|VP 16-213|VP-16
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
alpha-D-Glucopyranosyl isomer etoposide
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
Celltop
Demethyl epipodophyllotoxin ethylidine glucoside
Eposide
Eposin
Eto gry
Eto-gry
Etomedac
Etopophos
Etopos
ETOPOSIDE
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
|
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
Lastet
Lemery brand OF etoposide
Medac brand OF etoposide
Novartis brand OF etoposide
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Riboposid
Ribosepharm brand OF etoposide
Sanfer brand OF etoposide
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Teva, etoposide
Toposar
trans-Etoposide
Vepesid
Vepesid J
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16-213
VP-16
VP-16-213
Zuyeyidal
|
|
5 |
|
Lomustine |
Approved, Investigational |
Phase 3 |
|
13010-47-4 |
3950 |
Synonyms:
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-Chloroethyl)-3-cyclohexylnitrosourea
Belustine
Bristol myers squibb brand OF lomustine
Bristol-myers squibb brand OF lomustine
CCNU
CCN-U
Cecenu
CeeNU
Chloroethylcyclohexylnitrosourea
CINU
|
Cyclohexyl chloroethyl nitrosourea
Gleostine
Lomustina
LOMUSTINE
Lomustine medac brand
Lomustinum
Medac brand OF lomustine
N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea
NSC-79037
Rhône poulenc rorer brand OF lomustine
Rhône-poulenc rorer brand OF lomustine
|
|
6 |
|
Metformin |
Approved |
Phase 3 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
7 |
|
Povidone K30 |
Approved, Experimental, Withdrawn |
Phase 3 |
|
9003-39-8 |
6917 131751496 |
Synonyms:
1-Ethenyl-2-pyrrolidinone
1-Ethenyl-2-pyrrolidinone (9ci)
1-Ethenyl-2-pyrrolidinone homopolymer
1-Ethenyl-2-pyrrolidinone homopolymer, 9ci
1-Ethenyl-2-pyrrolidinone polymers
1-Ethenyl-2-pyrrolidinone, homopolymer
1-Vinyl-2-pyrrolidinone
1-Vinyl-2-pyrrolidinone cross-linked insoluble polymer
1-Vinyl-2-pyrrolidinone homopolymer
1-Vinyl-2-pyrrolidinone polymer
1-Vinyl-2-pyrrolidinone, monomer
1-Vinyl-2-pyrrolidinone, polymer
1-Vinyl-2-pyrrolidone
1-Vinyl-2-pyrrolidone polymer
1-Vinylpyrrolidin-2-one
1-vinylpyrrolidin-2-one homopolymer
1-Vinylpyrrolidinone
1-Vinylpyrrolidone
2-Pyrrolidinone, 1-ethenyl, homopolymer
2-Pyrrolidinone, 1-ethenyl-, homopolymer
2-Pyrrolidinone, 1-vinyl-, polymers
Agent at 717
Agent at-717
Agrimer
Albigen a
Aldacol Q
Alphadine
Alphadines
Antaron P 804
Arufil
Betadine
Betadines
Betaisodona
Betaisodonas
Bolinan
Bolinan 40
Crospovidone
Disadine
Disadines
Dulcilarme
Dulcilarmes
Duratears free
Enterode
Enterodes
Enterodez
Ganex P 804
Ganex P-804
Hemodesis
Hemodez
Huntington laboratories brand OF povidone iodine
Huntington laboratories brand OF povidone-iodine
Hypotear
Hypotears
Isodine
Isodines
K 115 (Polyamide)
K 25
K 25 (Polymer)
K 30
K 30 (Polymer)
K 60
K 60 (Polymer)
K115 (Polyamide)
K25 (Polymer)
K30 (Polymer)
K60 (Polymer)
Kollidin CLM
Kollidon
Kollidon 17
Kollidon 25
'Kollidon 25'
Kollidon 30
Kollidon CL
Lacophtal
Lacri-stulln
Lagrifilm
Liquifilm lagrimas
Luviskol
Luviskol K 30
Luviskol K 90
Luviskol K30
Luviskol K-30
Luviskol K90
N- Vinyl pyrrolidone
Neocompensan
Nutrivisc
N-Vinyl pyrrolidone
N-Vinyl-2-pyrrolidinone
N-Vinyl-2-pyrrolidone
N-Vinyl-2-pyrrolidone polymer
N-Vinylbutyrolactam polymer
N-Vinylpyrrolidinone
N-Vinylpyrrolidinone polymer
N-Vinylpyrrolidone
N-Vinylpyrrolidone polymer
N-Vinylpyrrolidone-2
Oculotect
Peragal ST
Peregal ST
Periston
Periston-N
Peviston
Pharmadine
Pharmadines
'plasdone'
Plasdone
Plasdone 4
Plasdone K 29-32
Plasdone K-26/28
Plasdone K29/32
Plasdone K29-32
|
Plasdone no. 4
Plasdone XL
Plasmosan
Polividone
Polvidone
Poly(1-(2-oxo-1-pyrrolidinyl)-1,2-ethanediyl)
Poly(1-(2-oxo-1-pyrrolidinyl)ethylene)
Poly(1-ethenyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone) homopolymer
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.1
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.2
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.3
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.4
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.5
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.6
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.7
Poly(1-vinyl-2-pyrrolidone)
Poly(1-vinylpyrrolidinone)
Poly(N-vinyl-2-pyrrolidinone)
Poly(N-vinyl-2-pyrrolidone)
Poly(N-vinylbutyrolactam)
Poly(N-vinylpyrrolidinone)
Poly(N-vinylpyrrolidone)
Poly(vinylpolypyrrolidone)
Poly(vinylpyrrolidinone)
Poly(vinylpyrrolidone)
Polyclar a. t
Polyclar a. t.
Polyclar at
Polyclar H
Polyclar L
Polyclar-at
Polygyl
Poly-N-vinyl pyrrolidone
Poly-N-vinylpyrrolidone
Polyplasdone
Polyplasdone XL
Polyvidon
Polyvidons
Polyvidonum
Polyvinyl pyrrolidone
Polyvinylpolypyrrolidone
Polyvinylpyrrolidone
Polyvinylpyrrolidone iodine
Polyvinylpyrrolidone iodines
Polyvinylpyrrolidone K 30
Polyvinylpyrrolidone K-29/32
Polyvinylpyrrolidone K30
Polyvinylpyrrolidone polymers
Polyvinylpyrrolidone, cross-linked
Povidona
Povidone
Povidone iodine
Povidone K29/32
Povidone K29-32
Povidone(usan)
Povidone, ban, usan
Povidone, unspecified
Povidone-iodine
Povidone-iodines
Povidonum
Protagen
Protagens
Protagent
Providine
Providines
PVP 1
PVP 2
PVP 3
PVP 4
PVP 40
PVP 5
PVP 6
PVP 7
PVP Iodine
PVP K 3
PVP K30
PVP K-30
PVP10_SIAL
PVP40_SIAL
PVP-I
PVP-Iodine
PVP-Iodines
PVP-K 15
PVP-K 3
PVP-K 30
PVP-K 60
PVP-K 90
PVPP
Refresh
Sauflon
Soothe
Subtosan
Tears plus
Tolpovidone I 131
Tolpovidone I-131
Toxobin
Unifluid
Unspecified povidone
Vidirakt S mit PVP
Vidisic PVP ophtiole
Vinisil
Vinyl-2-pyrrolidone
Vinylbutyrolactam
Vinylpyrrolidinone
Vinylpyrrolidinone polymer
Vinylpyrrolidone
Vinylpyrrolidone polymer
V-Pyrol
Wet-comod
|
|
8 |
|
Titanium dioxide |
Approved |
Phase 3 |
|
13463-67-7 |
|
Synonyms:
dióxido de titanio
óxido de titanio(4)
|
|
|
9 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 3 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
10 |
|
Picropodophyllin |
Approved, Investigational |
Phase 3 |
|
518-28-5, 477-47-4 |
10607 72435 |
Synonyms:
(−)-podophyllotoxin
(-)-Podophyllotoxin
6,7]NAPHTHO[2,3-D][1,3]DIOXOL-6(5AH)-ONE
9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDROFURO[3',4'
9-HYDROXY-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-D][1,3]dioxol-6(5ah)-one
Ardern brand OF podophyllotoxin
AXL-1717
AXL1717|podofilox
Canderm brand OF podophyllotoxin
Condyline
Condylox
CPH86
Epipodophyllotoxin
Fides ecopharma brand OF podophyllotoxin
Hamilton brand OF podophyllotoxin
Newport brand OF podophyllotoxin
NSC-24818
NSC-36407
Oclassen brand OF podophyllotoxin
Paddock brand OF podophyllotoxin
Paladin brand OF podophyllotoxin
|
PICROPODOPHYLLIN
PICROPODOPHYLLOTOXIN
PODOCON-25
Podofilm
Podofilox
Podophyllinate lactone
Podophyllinic acid lactone
Podophyllotoxin
Podophyllotoxin 7
PODOPHYLLOTOXIN PICROPODOPHYLLIN
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-isomer
PPT
Stiefel brand OF podophyllotoxin
Wartec
Warticon
Wolff brand OF podophyllotoxin
Yamanouchi brand OF podophyllotoxin
|
|
11 |
|
Irinotecan |
Approved, Investigational |
Phase 3 |
|
97682-44-5, 100286-90-6 |
60838 |
Synonyms:
(+)-Irinotecan
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Biotecan
Camptosar
Camptothecin 11
Camptothecin-11
CP0
CPT 11
CPT11
CPT-11
HSDB 7607
Irinophore C
IRINOTECAN
|
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
NK012 Compound
sn 38
sn-38
sn38 CPD
|
|
12 |
|
Temozolomide |
Approved, Investigational |
Phase 3 |
|
85622-93-1 |
5394 |
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
BRN 5547136
CCRG 81045
CCRG-81045
CCRIS 8996
m & b 39831
m And b 39831
m And b39831
m And b-39831
M&B 39831
M&B-39831
M-39831
MB 39831
Methazolastone
NSC 362856
NSC-362856
|
SCH 52365
SCH-52365
Temodal
Temodar
TEMOMEDAC
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide
Témozolomide
Temozolomide hexyl ester
Temozolomidum
Temozolomidum [Latin]
TMZ
TMZ Bioshuttle
TMZA-he
TMZ-Bioshuttle
|
|
13 |
|
Vinblastine |
Approved |
Phase 2, Phase 3 |
|
865-21-4 |
241903 13342 |
Synonyms:
(2a,2'b,3b,4a,5b)-VINCALEUKOBLASTINE
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2Α,2'β,3β,4α,5β)-vincaleukoblastine
[3H]-VINBLASTINE
29060-LE|Velban®|Velbe®|vincaleucoblastin|vincaleukoblastine
Cell pharm brand OF vinblastine sulfate
Cellblastin
EG labo brand OF vinblastine sulfate
Faulding brand OF vinblastine sulfate
Gastrozepin brand OF vinblastine sulfate
Gry brand OF vinblastine sulfate
Hexal brand OF vinblastine sulfate
Lemblastine
Lemery brand OF vinblastine sulfate
Lilly brand OF vinblastine sulfate
Nincaluicolflastine
NSC-47842
Rozevin
|
Sulfate, vinblastine
Velban
Velbe
Vinblastin
Vinblastin hexal
Vinblastina
Vinblastina [Dcit]
Vinblastina lilly
Vinblastine
Vinblastine sulfate
Vinblastinsulfat-gry
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
VLB
|
|
14 |
|
Daunorubicin |
Approved |
Phase 3 |
|
20830-81-3 |
30323 |
Synonyms:
(+)-Daunomycin
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Cerubidin
Cerubidine
Daunamycin
Daunarubicinum
Dauno rubidomycine
Daunoblastin
Daunoblastine
Daunomycin
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
DAUNORUBICIN
Daunorubicin Hcl
Daunorubicin hydrochloride
Daunorubicin, Hydrochloride
DAUNORUBICINA
|
DAUNORUBICINE
Daunorubicinum
Daunorubicinum [INN-Latin]
Dauno-rubidomycine
DaunoXome
DM
DM1
FI 6339
FI-6339
Hydrochloride, daunorubicin
Leukaemomycin C
NDC-0082-4155
NSC-83142
Ondena
Rcra Waste No. U059
RP 13057
Rp 13057 Hydrochloride
RP-13057
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
VALRUBICIN IMPURITY, DAUNORUBICIN
|
|
15 |
|
Dexrazoxane |
Approved, Withdrawn |
Phase 3 |
|
24584-09-6 |
71384 |
Synonyms:
(+)-(S)-4,4′-PROPYLENEDI-2,6-PIPERAZINEDIONE
(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione
(+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane
4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
ADR 529
ADR-529
Cardioxan
Cardioxane
Desrazoxane
Dexrazoxan
Dexrazoxane
Dexrazoxane hydrochloride
Dexrazoxano
Dexrazoxano [INN-Spanish]
Dexrazoxanum
Dexrazoxanum [INN-Latin]
Dextrorazoxane
|
DRX187
Dyzoxane
Eucardion
Hydrochloride, dexrazoxane
ICRF 187
Icrf-187
ICRF187
NSC-169780
Razoxana [INN-Spanish]
Razoxane
Razoxane, (S)-isomer
Razoxane, (S)-isomer, hydrochloride
Razoxanum [INN-Latin]
Razoxin
Tepirone
Troxozone
Zinecard
|
|
16 |
|
Grape |
Approved |
Phase 3 |
|
|
|
17 |
|
Cranberry |
Approved, Investigational |
Phase 3 |
|
|
|
18 |
|
Lenograstim |
Approved, Investigational |
Phase 3 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
19 |
|
Isotretinoin |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
302-79-4, 4759-48-2 |
5538 444795 5282379 |
Synonyms:
(13-cis)-Retinoate
(13-CIS)-RETINOIC ACID
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXENYL)NONA-2,4,6,8-TETRAENOIC ACID
(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate
(2Z,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAENOIC ACID
(7E,9E,11E,13Z)-Retinoate
(7E,9E,11E,13Z)-RETINOIC ACID
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
13 cis Retinoic acid
13 CIS-RETINOIC ACID
13-cis-Retinoate
13-cis-Retinoate,isotretinoin
13-CIS-RETINOIC ACID
13-CIS-VITAMIN A ACID
13-RA
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoate (ecl)
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
Aberel
ABSORICA
ACCUTANE
Acid, all-trans-retinoic
Acid, beta-all-trans-retinoic
Acid, retinoic
Acid, trans-retinoic
Acid, vitamin a
Acide retinoique
ACIDE RETINOIQUE (FRENCH)
ACIDE RETINOIQUE (FRENCH) (DSL)
ACTICIN
AGN 100335
Airol
Aknefug
Aknoten
all trans Retinoic acid
all trans-Retinoic acid
all-(e)-Retinoate
all-(e)-Retinoic acid
all-trans-beta-Retinoate
all-trans-beta-Retinoic acid
all-trans-b-Retinoate
all-trans-b-Retinoic acid
all-trans-Retinoate
all-trans-Retinoic acid
ALL-TRANS-RETINOIC ACID (ATRA)
all-trans-retinoic acid (ATRA)|Altreno® (0.05% lotion)|Avita® (0.025% gel)|Renova® (0.02% cream)
all-trans-Tretinoin
all-trans-Vitamin a acid
all-trans-Vitamin a1 acid
all-trans-Β-retinoate
all-trans-Β-retinoic acid
ALTRENO
AMNESTEEM
ATRA
Atra-IV
Atralin
Avita
beta all trans Retinoic acid
beta-all-trans-Retinoic acid
beta-Retinoate
beta-Retinoic acid
b-Retinoate
b-Retinoic acid
CIP-isotretinoin
CIS-RA
cis-Retinoate
|
CIS-RETINOIC ACID
CLARAVIS
Dermairol
Eudyna
ISOTRETINOIN
Isotretinoin zinc salt, 13 cis isomer
Isotretinoin zinc salt, 13-cis-isomer
Isotretinoina
Isotretinoína
Isotretinoine
Isotrétinoine
Isotretinoino
Isotretinoinum
ISOTREX
Lsotretinoin
MYORISAN
NEOVITAMIN A ACID
NSC-122758
PAT-001
Potassium salt, tretinoin
Renova
Retin a
Retin-a
Retin-a micro
RETIN-A-MICRO
Retinoate
Retinoic acid
RETINOIC ACID 13-CIS-FORM
Retionic acid
Retisol-a
Ro 1-5488
RO-43780
RO-4-3780
Roaccutan
ROACCUTANE
Roacutan
Salt, tretinoin potassium
Salt, tretinoin sodium
Salt, tretinoin zinc
Sodium salt, tretinoin
Solage
SOTRET
Stieva-a
Stieva-a Forte
Teriosal
trans Retinoic acid
trans-Retinoate
trans-Retinoic acid
Tretin m
Tretinoin
Tretinoin potassium salt
Tretinoin sodium salt
Tretinoin zinc salt
TRETINOIN、ATRA
Tretinoina
Trétinoïne
TRETINOINE (FRENCH)
TRETINOINE (FRENCH) (EINECS)
Tretinoinum
Tretin-X
Tri-Luma
Vesanoid
Vitamin a acid
Vitinoin
ZENATANE
Zinc salt, tretinoin
Β-retinoate
Β-retinoic acid
|
|
20 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
22737-96-8, 68-26-8 |
5280382 445354 |
Synonyms:
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAEN-1-OL
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL
11-CIS-RETINOL
11-cis-Vitamin a alcohol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-e)-isomer
all trans Retinol
all-trans-Retinol
ALL-TRANS-RETINYL ALCOHOL
ALL-TRANS-VITAMIN A ALCOHOL
ALPHALIN
Aquasol a
AROVIT
BETA-RETINOL
B-RETINOL
CHOCOLA A
cis-11-Retinol
|
NEPALM
NSC-122759
OLEOVITAMIN A
Retinol
RETINOL (VIT A)
RETINOL ACETATE
RETINOL PALMITATE
Retinolum
RO-A-VIT
TRANS-RETINOL
Vitamin a
VITAMIN A 1
VITAMIN A OIL
VITAMIN A SOLUBILIZED
Vitamin a1
|
|
21 |
|
Trofosfamide |
Investigational |
Phase 2, Phase 3 |
|
22089-22-1 |
65702 |
Synonyms:
A-4828
Genoxal trofosfamida
Ixoten
N,N,N'-tris(2-chloroethyl)-n'-O-propylene phosphoric acid ester diamide
NSC-109723
|
TROFOSFAMIDE
Trophosphamide
Z-4828
Z-4828a-4828Trophosphamide
|
|
22 |
|
Camptothecin |
Experimental |
Phase 3 |
|
7689-03-4 |
24360 |
Synonyms:
(+)-camptothecin
(+)-camptothecine
(S)-(+)-camptothecin
(S)-CAMPTOTHECIN
20(S)-CAMPTOTHECIN
20(S)-camptothecine
|
21,22-Secocamptothecin-21-oic acid lactone
CAMPTOTHECIN
Camptothecine
CPT
D-camptothecin
NSC-94600
|
|
23 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
24 |
|
Etoposide phosphate |
|
Phase 3 |
|
|
16760419 |
Synonyms:
{4-[16-({7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-D][1,3]dioxin-6-yl}oxy)-12-oxo-4,6,13-trioxatetracyclo[7.7.0.0,.0,]hexadeca-1,3(7),8-trien-10-yl]-2,6-dimethoxyphenoxy}phosphonate
BMY-40481
ETOPOPHOS
ETOPOPHOS PRESERVATIVE FREE
|
ETOPOSIDE PHOSPHATE
Etoposide phosphoric acid
VP16
VP-16
|
|
25 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
26 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
27 |
|
Antidotes |
|
Phase 3 |
|
|
|
28 |
|
Chelating Agents |
|
Phase 3 |
|
|
|
29 |
|
Liver Extracts |
|
Phase 3 |
|
|
|
30 |
|
Hypoglycemic Agents |
|
Phase 3 |
|
|
|
31 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
32 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
33 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
34 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3 |
|
|
|
35 |
|
Keratolytic Agents |
|
Phase 3 |
|
|
|
36 |
|
Dermatologic Agents |
|
Phase 3 |
|
|
|
37 |
|
Protective Agents |
|
Phase 3 |
|
|
|
38 |
|
Vitamins |
|
Phase 3 |
|
|
|
39 |
|
Trace Elements |
|
Phase 3 |
|
|
|
40 |
|
Micronutrients |
|
Phase 3 |
|
|
|
41 |
|
Retinol palmitate |
|
Phase 3 |
|
|
|
42 |
|
topoisomerase I inhibitors |
|
Phase 3 |
|
|
|
43 |
|
Vaccines |
|
Phase 3 |
|
|
|
44 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
45 |
|
Cardiotonic Agents |
|
Phase 3 |
|
|
|
46 |
|
Razoxane |
|
Phase 3 |
|
|
|
Synonyms:
(+,-)-1,2-Bis(3,5-dioxopiperazine-1-yl)propane
Cardioxane
ICI-59118
ICRF 159
ICRF 186
ICRF159
ICRF-159
ICRF186
|
ICRF-186
Razoxana
RAZOXANE
Razoxane mesylate, (R)-isomer
Razoxane, (R)-isomer
Razoxanum
Razoxin
|
|
47 |
|
3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione |
|
Phase 3 |
|
|
|
48 |
|
Sodium thiosulfate |
|
Phase 3 |
|
|
|
Synonyms:
Anhydrous sodium thiosulfate
Anhydrous sodium thiosulfuric acid
Anhydrous sodium thiosulphate
Anhydrous sodium thiosulphuric acid
Disodium thiosulfate
Disodium thiosulfuric acid
Disodium thiosulphate
Disodium thiosulphuric acid
Pentahydrate OF sodium thiosulfate
Sodium hyposulfite
Sodium hyposulphite
Sodium oxide sulfide
Sodium oxide sulphide
|
Sodium thiosulfate (anhydrous)
Sodium thiosulfate anhydrous
Sodium thiosulfate pentahydrate
Sodium thiosulfuric acid
Sodium thiosulfuric acid (anhydrous)
Sodium thiosulphate
Sodium thiosulphate (anhydrous)
Sodium thiosulphuric acid
Sodium thiosulphuric acid (anhydrous)
Thiosulfate, disodium salt
Thiosulfuric acid, disodium salt
Thiosulphate, disodium salt
Thiosulphuric acid, disodium salt
|
|
49 |
|
Antitubercular Agents |
|
Phase 3 |
|
|
|
50 |
|
Antioxidants |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 287)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue |
Recruiting |
NCT02875314 |
Phase 4 |
Induction;Single Cycle Intensive Chemotherapy;Tandem 3 Cycle Intensive Chemotherapy |
2 |
A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma |
Unknown status |
NCT00053872 |
Phase 3 |
cisplatin;lomustine;vincristine sulfate |
3 |
A Prospective Randomised Controlled Trial of Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma |
Unknown status |
NCT01351870 |
Phase 3 |
|
4 |
Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma |
Completed |
NCT02040376 |
Phase 3 |
Metformin;Placebo |
5 |
Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= to 8 Months and <3 Years With Non-metastatic Medulloblastoma: A Children's Oncology Group Phase III Study |
Completed |
NCT00006461 |
Phase 3 |
cisplatin;cyclophosphamide;vincristine sulfate;etoposide |
6 |
A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children |
Completed |
NCT00716976 |
Phase 3 |
sodium thiosulfate |
7 |
Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents |
Completed |
NCT00749723 |
Phase 2, Phase 3 |
carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;intraventricular etoposide;trofosfamide, etoposide |
8 |
Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA |
Completed |
NCT00002875 |
Phase 3 |
cisplatin;cyclophosphamide;lomustine;mesna;vincristine sulfate |
9 |
Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood |
Completed |
NCT00003859 |
Phase 3 |
carboplatin;cyclophosphamide;etoposide;vincristine sulfate |
10 |
Phase III Randomized Double-blind Placebo-controlled Trial of Metformin for Cognitive Recovery and White Matter Growth in Paediatric Medulloblastoma Patients |
Recruiting |
NCT05230758 |
Phase 3 |
Metformin hydrochloride (HCl) 500mg tablet;Placebo |
11 |
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients |
Active, not recruiting |
NCT00392327 |
Phase 3 |
Carboplatin;Cisplatin;Cyclophosphamide;Isotretinoin;Vincristine Sulfate |
12 |
AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB - LR and PNET 5 MB - WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR), OR TP53 MUTATION, AND REGISTRY FOR MB OCCURRING IN THE CONTEXT OF GENETIC PREDISPOSITION |
Active, not recruiting |
NCT02066220 |
Phase 2, Phase 3 |
Reduced-intensity maintenance chemotherapy;Maintenance chemotherapy;Induction Chemotherapy;Vinblastin Maintenance |
13 |
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial |
Active, not recruiting |
NCT00085735 |
Phase 3 |
Cisplatin;Cyclophosphamide;Lomustine;Vincristine Sulfate |
14 |
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate |
Active, not recruiting |
NCT00336024 |
Phase 3 |
etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate |
15 |
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor |
Active, not recruiting |
NCT00085202 |
Phase 3 |
cisplatin;cyclophosphamide;vincristine |
16 |
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma |
Active, not recruiting |
NCT02306161 |
Phase 3 |
Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate |
17 |
A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma |
Active, not recruiting |
NCT01231906 |
Phase 3 |
Cyclophosphamide;Dexrazoxane;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate |
18 |
A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma |
Active, not recruiting |
NCT03495921 |
Phase 3 |
Irinotecan;Temozolomide |
19 |
A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features |
Not yet recruiting |
NCT05382338 |
Phase 3 |
Cisplatin;Cyclophosphamide;Lomustine;Mesna;Sodium Thiosulfate;Vincristine |
20 |
Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer |
Terminated |
NCT01987596 |
Phase 3 |
|
21 |
Phase 2 Study of Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Medulloblastoma |
Unknown status |
NCT02681705 |
Phase 2 |
Temozolomide |
22 |
Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Metastatic (M1-3) Medulloblastoma |
Unknown status |
NCT00276666 |
Phase 2 |
cisplatin;lomustine;vincristine sulfate |
23 |
National, Multicentric, Prospective Phase II Study Estimating the Interest of a Dose Decrease for Radiation Therapy Associated With a Carboplatine and Etoposide Based Chemotherapy for the Treatment of Standard Risk Adult Medulloblastomas |
Unknown status |
NCT01857453 |
Phase 2 |
carboplatine;Etoposide |
24 |
Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy |
Unknown status |
NCT00180791 |
Phase 2 |
Etoposide, carboplatin, melphalan, cisplatin, thiotepa |
25 |
Phase II Study of Vinorelbine + Cyclofosfamide Association Among Patients Reached of Refractory Tumours or in Relapse |
Unknown status |
NCT00180947 |
Phase 2 |
Vinorelbine, cyclofosfamide |
26 |
Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Non-Pineal Supratentorial Primitive Neuroectodermal Tumours |
Unknown status |
NCT00274911 |
Phase 2 |
cisplatin;lomustine;vincristine sulfate |
27 |
A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma |
Completed |
NCT01125800 |
Phase 1, Phase 2 |
LDE225 |
28 |
Comparator Study of 68Ga-DOTATOC PET/CT With Octreoscan + High-resolution, Contrast-enhanced CT for Diagnosis and Staging in Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors |
Completed |
NCT01869725 |
Phase 2 |
gallium Ga 68-edotreotide |
29 |
Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial |
Completed |
NCT01217437 |
Phase 2 |
Irinotecan Hydrochloride;Temozolomide |
30 |
A Phase II, Multi-center, Open-label, Single-arm Study of the Efficacy and Safety of Oral LDE225 in Patients With Hh-pathway Activated Relapsed Medulloblastoma |
Completed |
NCT01708174 |
Phase 2 |
LDE225;TMZ |
31 |
Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma. |
Completed |
NCT00404495 |
Phase 2 |
Irinotecan;Temozolomide |
32 |
Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma |
Completed |
NCT00095940 |
Phase 1, Phase 2 |
lapatinib ditosylate |
33 |
A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma |
Completed |
NCT00070525 |
Phase 2 |
tipifarnib |
34 |
A Phase II Study of Oxaliplatin in Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors |
Completed |
NCT00047177 |
Phase 2 |
Oxaliplatin |
35 |
A Phase I/II Feasibility Study of Oral Etoposide Given Concurrently With Radiotherapy Followed With Dose Intensive Adjuvant Chemotherapy for Children With Newly Diagnosed High Stage Medulloblastoma |
Completed |
NCT00003573 |
Phase 2 |
cisplatin;cyclophosphamide;etoposide;vincristine sulfate |
36 |
Dose-Intensive Melphalan and Cyclophosphamide With Autologous Bone Marrow Rescue for Recurrent Medulloblastoma and Germ Cell Tumors |
Completed |
NCT00002594 |
Phase 2 |
cyclophosphamide;melphalan |
37 |
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma |
Completed |
NCT00939484 |
Phase 2 |
Vismodegib |
38 |
Treatment of Newly Diagnosed Medulloblastoma and Supratentorial PNET in Patients At Least 3 Years With a Phase II Topotecan Window (High-Risk Patients Only), Risk-Adapted Radiation Therapy, and Dose-Intensive Chemotherapy With Peripheral Blood Stem Cell Support |
Completed |
NCT00003211 |
Phase 2 |
amifostine trihydrate;cisplatin;cyclophosphamide;vincristine sulfate |
39 |
A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma |
Completed |
NCT00003309 |
Phase 2 |
cisplatin;cyclophosphamide;etoposide;vincristine sulfate |
40 |
Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults (NOA-07) |
Completed |
NCT01614132 |
Phase 1, Phase 2 |
maintenance chemotherapy (vincristin, cisplatin and CCNU) |
41 |
Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation |
Completed |
NCT00006258 |
Phase 2 |
cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate |
42 |
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma |
Completed |
NCT01239316 |
Phase 2 |
Vismodegib |
43 |
Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET |
Completed |
NCT01542736 |
Phase 2 |
Carboplatin;Vincristine |
44 |
A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM |
Completed |
NCT01977677 |
Phase 1, Phase 2 |
temozolomide;plerixafor |
45 |
A Phase II Study of Pemetrexed in Children With Recurrent Malignancies |
Completed |
NCT00520936 |
Phase 2 |
pemetrexed |
46 |
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020) |
Completed |
NCT04730349 |
Phase 1, Phase 2 |
|
47 |
Phase 2 Single-Arm Studies of Gemcitabine in Combination With Oxaliplatin Refractory and Relapsed Pediatric Solid Tumors |
Completed |
NCT00407433 |
Phase 2 |
Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®) |
48 |
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas |
Completed |
NCT00381797 |
Phase 2 |
Irinotecan Hydrochloride |
49 |
Safety & Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging & Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT. |
Completed |
NCT01619865 |
Phase 1, Phase 2 |
68Ga-DOTATOC PET/CT |
50 |
A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients With Refractory Meningeal Malignancies |
Completed |
NCT00005811 |
Phase 2 |
topotecan hydrochloride |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Cochrane evidence based reviews: medulloblastoma
|